Home
Transactions

Work Area: Transactions

IAM Market moves to the IAM platform

The global marketplace allows IP rights owners to present assets for license, sale or transfer to our unique audience of senior decision takers and deal makers

Via LA exits Alium O-RAN patent pool, leaving Unified Patents to administrate

“In 2022 we chose to wind down our wireless patent pools. Consistent with that decision, we are also exiting the Alium partnership,” states Via LA President Heath Hoglund

South Korea’s IP-backed lending market growth exceeds targets

Although heavy reliance on government-backed initiatives creates uncertain future for IP holders

Latest content

Sanofi farms out more IP as part of “play to win” strategy

The French company is one of several big pharmas to have offloaded deprioritised drugs in recent months

29 July 2022

Be proactive about IP ownership

Employees are not necessarily always renumerated for their patented or patentable inventions. Therefore, employers are advised to take a number of steps to avoid disruptive issues over the ownership of intellectual property created by their employees.

27 July 2022

UK government blocks IP deal with Chinese company using radical new powers

Recently implemented legislation gives the British government the ability to intervene in IP transactions

22 July 2022

Patent ownership when your R&D staff depart

IP transactions face difficulties when inventor employees leave a company, raising questions as to whether their inventions are owned by the company. Often, the type of employee and the jurisdiction in question are key factors.

20 July 2022

Royalty Pharma spends $1.3 billion in latest drug revenue rights purchase

Royalty transactions are an increasingly attractive means of cashing in on life sciences innovation, and the returns can be significant

15 July 2022

Pfizer to commercialise its IP with the help of trailblazing Roivant approach

The partnership is aimed at helping the pharma giant to moentise deprioritised IP in the autoimmune space

04 July 2022

Data monetisation gathers momentum in the healthcare sector

Life sciences innovators are increasingly paying for access to high-quality data

27 June 2022

BlackBerry CEO “responding to the calls” of other bidders for the company’s patents

John Chen says there’s a high probability that Catapult IP Innovations will still buy the portfolio, but he wants shareholders to know he’s “not just stuck with one option”

24 June 2022

Change at the top of Xiaomi’s IP Strategy team

After six years in charge, Paul Lin steps down to go solo, although he will remain an adviser to the Chinese company

23 June 2022

Why IP valuation in Asia has yet to take off

Although various government-led programmes have emerged over the years to encourage activity in the field, writes Joyce Ng, professionals reveal that a lack of transaction data and an absence of corporate buy-in is preventing it from going mainstream

22 June 2022

Unlock unlimited access to all IAM content